Clinical Trial Update: Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is investigating the combination of efineptakin alfa with pembrolizumab for recurrent glioblastoma and related high-grade astrocytic tu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma High Grade
• Glioblastoma Idh-wildtype
• Gliosarcoma

Drugs mentioned

• Efineptakin alfa (efineptakin alfa)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Mayo Clinic | Conditions: High Grade Astrocytic Tumor, Recurrent Glioblastoma, IDH-Wildtype | Phase 2 | Status: RECRUITING